GSK583 is a selective inhibitor of RIP2 Kinase and IC50 value is 5 nM.

RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM[1].

Necrostatin-1 is an inhibitor of RIP1 and can decrease TNF-α-induced necroptosis with EC50 of 490 nM.

Nec-34 can synergize with Nec-1s to inhibit RIPK1 in vitro and in vivo.

RIP2 kinase inhibitor 1 is a receptor interacting protein-2 (RIP2) kinase inhibitor.

RIPA-56 is a RIP1 inhibitor with EC50 value of 28nM. It efficiently reduced TNFα-induced mortality and multi-organ damage.

GSK2983559 free acid is a small-molecule inhibitor of RIP2 kinase. GSK2983559 free acid potently binds to RIP2 kinase with good kinase specificity and has excellent activity in blocking many proinflammatory cytokine responses in vivo .

HS1371 is an ATP-competitive and novel kinase inhibitor of RIP3-mediated necroptosis which can directly bind to RIP3.

GSK'547 is a highly selective and potent RIP1 inhibitor with improved oral bioavailability.

GSK'481 can inhibit RIP1 WT S166 phosphorylation in human vs mouse plasmids overexpressed in HEK293T cells.

GSK3145095 is a potent and orally active RIPK1 inhibitor with IC50 of 5 nM and potential antineoplastic and immunomodulatory activities.

GSK2982772 is an inhibitor of receptor interacting protein 1 (RIP1) with IC50 of 16 nM and it is used for the treatment of inflammatory diseases.

Resibufogenin, a natural product isolated and purified from the glandular body of Bufo bufo gargarizans Cantor, displays great potential as a chemotherapeutic agent in oncology.